Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$172.92
-1.8%
$173.94
$163.33
$251.99
$49.56B0.252.07 million shs2.50 million shs
Cencora, Inc. stock logo
COR
Cencora
$302.43
+2.1%
$291.12
$218.65
$309.35
$58.62B0.571.51 million shs1.60 million shs
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$76.64
-0.2%
$76.12
$58.93
$95.25
$44.96B1.115.24 million shs2.50 million shs
McKesson Corporation stock logo
MCK
McKesson
$735.41
+2.2%
$714.17
$464.42
$736.96
$92.01B0.48927,042 shs999,194 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.00%+3.12%+1.55%-14.02%-22.66%
Cencora, Inc. stock logo
COR
Cencora
0.00%-1.16%+2.50%+7.88%+33.03%
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
0.00%-1.67%-1.02%+11.26%-16.84%
McKesson Corporation stock logo
MCK
McKesson
0.00%-0.92%+0.89%+8.78%+22.38%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
4.9568 of 5 stars
4.23.03.34.03.62.51.3
Cencora, Inc. stock logo
COR
Cencora
4.6565 of 5 stars
2.43.03.33.13.53.31.3
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
4.3213 of 5 stars
2.23.00.04.02.42.52.5
McKesson Corporation stock logo
MCK
McKesson
4.3005 of 5 stars
1.45.03.33.02.82.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
2.36
Hold$219.2226.78% Upside
Cencora, Inc. stock logo
COR
Cencora
2.82
Moderate Buy$306.331.29% Upside
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
2.40
Hold$80.204.65% Upside
McKesson Corporation stock logo
MCK
McKesson
2.86
Moderate Buy$696.42-5.30% Downside

Current Analyst Ratings Breakdown

Latest MCK, COR, BDX, and EW Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Cencora, Inc. stock logo
COR
Cencora
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$275.00 ➝ $300.00
6/11/2025
McKesson Corporation stock logo
MCK
McKesson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$745.00 ➝ $770.00
6/3/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$261.00 ➝ $241.00
6/3/2025
Cencora, Inc. stock logo
COR
Cencora
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$274.00 ➝ $337.00
6/3/2025
McKesson Corporation stock logo
MCK
McKesson
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$691.00 ➝ $766.00
6/2/2025
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
Dbs Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
5/22/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$217.00 ➝ $185.00
5/22/2025
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$84.00 ➝ $95.00
5/13/2025
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$80.00 ➝ $83.00
5/9/2025
McKesson Corporation stock logo
MCK
McKesson
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$755.00 ➝ $800.00
5/8/2025
Cencora, Inc. stock logo
COR
Cencora
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$330.00 ➝ $355.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$20.18B2.46$20.76 per share8.33$89.57 per share1.93
Cencora, Inc. stock logo
COR
Cencora
$293.96B0.20$20.30 per share14.90$4.04 per share74.86
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$5.44B8.26$2.73 per share28.12$17.06 per share4.49
McKesson Corporation stock logo
MCK
McKesson
$359.05B0.26$39.73 per share18.51($13.52) per share-54.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.71B$5.2433.0011.061.337.28%15.99%7.36%8/7/2025 (Estimated)
Cencora, Inc. stock logo
COR
Cencora
$1.51B$8.6235.0817.921.470.55%344.71%4.26%8/6/2025 (Confirmed)
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$4.17B$7.0010.9527.873.8675.48%16.62%12.64%7/23/2025 (Estimated)
McKesson Corporation stock logo
MCK
McKesson
$3.30B$25.8328.4720.071.440.92%-201.12%5.83%8/6/2025 (Estimated)

Latest MCK, COR, BDX, and EW Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q3 2025
Cencora, Inc. stock logo
COR
Cencora
$3.79N/AN/AN/A$80.34 billionN/A
7/23/2025Q2 2025
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$0.62N/AN/AN/A$1.49 billionN/A
5/8/2025Q4 2025
McKesson Corporation stock logo
MCK
McKesson
$9.83$10.12+$0.29$10.01$94.00 billion$90.82 billion
5/7/2025Q2 2025
Cencora, Inc. stock logo
COR
Cencora
$4.07$4.42+$0.35$3.68$75.41 billion$75.50 billion
5/1/2025Q2 2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.28$3.35+$0.07$1.06$5.35 billion$5.27 billion
4/23/2025Q1 2025
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$0.60$0.64+$0.04$0.61$1.40 billion$1.41 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$4.162.41%N/A79.39%53 Years
Cencora, Inc. stock logo
COR
Cencora
$2.200.73%N/A25.52%15 Years
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
N/AN/AN/AN/AN/A
McKesson Corporation stock logo
MCK
McKesson
$2.840.39%N/A10.99%17 Years

Latest MCK, COR, BDX, and EW Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/1/2025
McKesson Corporation stock logo
MCK
McKesson
quarterly$0.710.4%6/2/20256/2/20257/1/2025
4/29/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
quarterly$1.042.02%6/9/20256/9/20256/30/2025
5/8/2025
Cencora, Inc. stock logo
COR
Cencora
quarterly$0.550.8%5/16/20255/16/20256/2/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.70
1.13
0.64
Cencora, Inc. stock logo
COR
Cencora
6.01
0.87
0.52
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
0.06
4.45
3.66
McKesson Corporation stock logo
MCK
McKesson
N/A
0.90
0.53

Institutional Ownership

CompanyInstitutional Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
Cencora, Inc. stock logo
COR
Cencora
97.52%
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
79.46%
McKesson Corporation stock logo
MCK
McKesson
85.07%

Insider Ownership

CompanyInsider Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.36%
Cencora, Inc. stock logo
COR
Cencora
10.80%
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
0.34%
McKesson Corporation stock logo
MCK
McKesson
0.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
74,000286.61 million285.58 millionOptionable
Cencora, Inc. stock logo
COR
Cencora
46,000193.82 million172.89 millionOptionable
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
15,800586.60 million584.61 millionOptionable
McKesson Corporation stock logo
MCK
McKesson
45,000125.11 million125.01 millionOptionable

Recent News About These Companies

Leerink Partners Sticks to Its Buy Rating for McKesson (MCK)
McKesson (NYSE:MCK) Upgraded by Wall Street Zen to Strong-Buy Rating
McKesson (MCK) Gets a Buy from J.P. Morgan
Q1 Earnings Forecast for McKesson Issued By Leerink Partnrs

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Becton, Dickinson and Company stock logo

Becton, Dickinson and Company NYSE:BDX

$172.92 -3.24 (-1.84%)
As of 03:59 PM Eastern

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Cencora stock logo

Cencora NYSE:COR

$302.43 +6.20 (+2.09%)
As of 03:59 PM Eastern

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

Edwards Lifesciences stock logo

Edwards Lifesciences NYSE:EW

$76.64 -0.15 (-0.20%)
As of 03:58 PM Eastern

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

McKesson stock logo

McKesson NYSE:MCK

$735.41 +16.11 (+2.24%)
As of 03:58 PM Eastern

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners, and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.